142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

Answering needs and deficits: The 2013 APHA Cancer genomics in public health policy statement

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Monday, November 17, 2014 : 10:50 AM - 11:10 AM

Stephen M. Modell, MD, MS , Epidemiology, and Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI
Chikezie C. Maduka, MA, PhD , University of Maryland PRC, Seat Pleasant University of Maryland Health Partnership, College Park, MD
Esha Mathew, BS, MEng , University of Michigan Comprehensive Cancer Center, Ann Arbor
Two powerful forces are coming together in cancer genetic testing to produce a population-wide impact: the development of an evidence base for tiered levels of oncogenomic testing (predictive testing for BRCA mutations and Lynch syndrome achieving highest validity), and enhanced availability of testing through judicial patenting changes and the Affordable Care Act. Groups experiencing disparities – Latinos and African Americans (half as likely as whites to receive cancer genetic testing and counseling) and those living in rural areas – can benefit now if suitable policies are achieved. In this session we will detail the 2013 APHA “Advancing Cancer Genomics in Public Health” policy statement spearheaded by the APHA Genomics Forum, and connect it with recent events in public health. Topics to be covered include: new developments in cancer family history and the rise of cascade screening; the varieties of cancer genetic testing that have emerged, from predictive testing to cancer pharmacogenomics; the antipodes of state-level cancer genetic surveillance programs and personalized, direct-to-consumer cancer genetic testing; and educational programs informed by public health provider and consumer needs. Genetic databases and genome-wide association studies must include data representing a diversity of cultural backgrounds and levels of exposure impacting genes. Recommendations falling into 4 categories (information-related (including electronic systems), intervention (testing, counseling, education)-related, disparities-oriented, and regulatory) will be covered. Together we will look at the action question of whether current policies (genetic testing guidelines, state educational-surveillance programs, Medicare and Medicaid coverage) are enough.

Learning Areas:

Chronic disease management and prevention
Clinical medicine applied in public health
Diversity and culture
Ethics, professional and legal requirements
Public health or related organizational policy, standards, or other guidelines
Public health or related public policy

Learning Objectives:
List two examples each of cancer genomic predictive and diagnostic testing Articulate the goals of genome-wide association studies and gene expression profiling for four cancer types Cite two policy approaches to the challenges posed by direct-to-consumer oncogenomic testing Supply an example each of recent professional society, institutional (health care system), and governmental (judicial, legislative, and regulatory) policies in cancer genomics Assess whether current Medicaid and Medicare policies are sufficient to cover genetic testing and counseling for familial breast and ovarian cancer and Lynch syndrome for individuals at-risk

Keyword(s): Genetics, Cancer

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the Dissemination Activities Director of the University of Michigan Center for Public Health and Community Genomics, having engaged in the teaching and research of genomics policy since 1992. I have multiple publications in the area of public health genomics, technical and policy aspects. I served as the chair of the APHA Genomics Forum Policy Committee from 2012-2013, and was principal author of the 2013 APHA "Advancing Cancer Genomics in Public Health" policy statement.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.